Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
John Laurence Kulp III · CONIFER POINT PHARMACEUTICALS, LLC · 2020 · $225,000 — Abstract Significance: To date, no specific therapeutic drug or vaccine has been approved for the treatment of human coronavirus. Better, direct-acting anti-viral drugs and accelerated methods for identifying them are desperately needed. Having a large body of diverse fragment binding simulation dat…
Joren C Madsen · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $361,494 — PROJECT SUMMARY / ABSTRACT The rapid progression of the SARS-CoV-2 pandemic and associated COVID-19 disease in the first 3 months of 2020 highlight the urgent need for research to understand the pathogenesis of the disease at the cellular level and how the immune system responds to this infection. A…
CHERYL LYNN WILLMAN · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · 2020 · $373,749 — A vaccine against SARS-CoV2 is badly needed. We have developed a vaccine platform technology based on virus-like particles (VLPs) of RNA phages like MS2, PP7, AP205 and Qß. When displayed multivalently on these bionanoparticles, peptide and protein antigens acquire a high level of immunogenicity. Th…
Jeffrey Cohen · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $112,386 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related disease and death. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune re…
Joshua Hoong Yu Tan · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $875,573 — The overarching goal of this project is to study the immune response to pathogens at the monoclonal level to increase our understanding of basic biology and develop new tools to combat disease. We are currently focusing our efforts on human monoclonal antibodies against two pathogens, Plasmodium fal…
Yu-Hua Tseng · JOSLIN DIABETES CENTER · 2021 · $606,855 — Project Summary/Abstract Obesity is growing at epidemic rates worldwide and leads to a broad spectrum of other disorders, which collectively form metabolic syndrome. Central to these pathologies is the adipose tissue. In mammals, there are two functionally distinct types of fat: white adipose tissu…
Forrest M Kievit · UNIVERSITY OF NEBRASKA LINCOLN · 2021 · $446,587 — PROJECT SUMMARY/ABSTRACT Traumatic brain injury (TBI) is the leading cause of disability and death in people under 45 with approximately 10 million new cases each year worldwide. The effects of TBI can be severe, including neurocognitive, physical, and psychosocial impairment. There remains a signi…
Marco E Zamora · DREXEL UNIVERSITY · 2021 · $46,036 — Proposal Summary/Abstract Acute respiratory distress syndrome (ARDS) is an acute inflammation of the lungs. It represents 10% of all intensive care unit (ICU) admissions in the United States. Despite decades of research and numerous large clinical trials, there are few treatments for ARDS. This lack…
Nathan Claude Gianneschi · NORTHWESTERN UNIVERSITY AT CHICAGO · 2021 · $398,137 — Project Summary The Polymeric Materials Synthesis and Characterizations Core will formulate, synthesize, and characterize lead candidates for the mitigation of mustards and provide support and chemical expertise to other cores and projects. The Core will be co-directed by Drs. Nathan Gianneschi (Dep…
Thomas William Geisbert · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $770,799 — PROJECT SUMMARY - Research Project 3 Members of the filovirus genera Ebolavirus and Marburgvirus are HHS Tier 1 Category A priority pathogens that cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates (NHPs). There are presently no approved therapeutics for ebolavirus o…
THOMAS HASSELL · INTERNATIONAL AIDS VACCINE INITIATIVE · 2021 · $1,595,794 — NIAID Process Development and Analytical Support for Development of HIV Vaccines: The development of vaccines to prevent the spread of HIV infection is among the National Institute of Allergy and Infectious Diseases (NIAID) highest priorities. While advances in immunology and molecular biology conti…
AJAY NMN RANA · JESSE BROWN VA MEDICAL CENTER · 2021 — Project Summary/Abstract: The main focus of research in our group is to understand the underlying molecular mechanisms of pancreatic and breast cancer pathogenesis. The overarching goal of our research is to investigate how the cellular pathways (i.e. circuits) are dysregulated and can lead to uncon…
Haifa Shen · METHODIST HOSPITAL RESEARCH INSTITUTE · 2021 · $463,570 — The tumor vasculature is generally considered as leaky, and thus allows accumulation of big molecules and particles within a certain size range to penetrate and retain. Consequently, many cancer drugs have been packaged into simple nanoparticles or composite drug particles in order to improve accumu…
Kerry S Campbell · THOMAS JEFFERSON UNIVERSITY · 2021 · $510,193 — Project Summary NK cells are capable of killing virus-infected and cancer cells and, therefore, play an important role in innate host defense. Unlike cytotoxic T lymphocytes (CTL), whose cytolytic activity is induced by productive TCR engagement with cognate pMHC ligands, activation of NK cells is r…
Song Li · UNIVERSITY OF ILLINOIS AT CHICAGO · 2021 · $428,652 — The amplification of Estrogen, Progesterone and Human Epidermal Growth Factor receptors (i.e. ER, PR and HER2) serve as prognostic markers in breast cancer. The prognosis of ER+ breast cancer is relatively better due to availability of several drugs that essentially block ER-signaling. However, HER2…
Teri Wang Odom · NORTHWESTERN UNIVERSITY · 2021 · $197,807 — PROJECT SUMMARY This proposal aims to develop live-cell, multi-channel imaging tools that can visualize—continuously, and in real time—nanoparticle interactions with cellular components. We will focus on several different time windows, where early time periods will monitor nanoparticle-cell membran…
Kent Lai · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2021 · $228,750 — PROJECT SUMMARY / ABSTRACT Hereditary deficiency of galactose-1-phosphate uridylyltransferase (GALT, E.C. 2.7.7.12) activity in humans can lead to a potentially lethal disease called Classic Galactosemia (OMIM 230400). Despite the life-saving consequences of newborn screening, early diagnosis, and …
Weihua Qiu · VIRGINIA COMMONWEALTH UNIVERSITY · 2021 · $229,008 — SUMMARY Connexin 26, as a gap junction channel, directly regulates the cell-to-cell exchange of ion, metabolites, and second messengers. Mutations of connexin 26 can cause severe hearing loss. However, the molecular gating mechanism on the structural basis of connexin 26 is still unclear, especially…
Gaurav Sahay · OREGON STATE UNIVERSITY · 2021 · $658,627 — ABSTRACT: Cystic fibrosis (CF) is conferred by any of ≥1200 known mutations in the gene encoding the CFTR, an ion transporter protein, but in principle, a single gene therapy agent that delivers expression of functional CFTR could treat. Prior attempts to do so have used adeno-associated viral or li…
JENNIFER A DOUDNA · UNIVERSITY OF CALIFORNIA BERKELEY · 2021 · $776,316 — PROJECT SUMMARY / ABSTRACT CRISPR-Cas9 has demonstrated incredible potential to provide clinical benefit, but the challenge of delivery currently hinders therapeutic use of genome editing in vivo. Use of viral vectors and lipid nanoparticles has established the viability of in vivo genome editing, b…